Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* In the investigator's clinical judgment, participants must be either in good or stable health. Participants may have underlying illnesses such as hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their signs and symptoms are stable and medically controlled in the judgment of the investigator. Participants will be included on the basis of medical history and of physical examination and vital signs performed at screening (all cohorts), and of physical examination and/or vital signs performed prevaccination on Day 1 (Cohorts 2 and 3)~* A woman must be postmenopausal (defined as no menses for 12 months without an alternative medical cause) and not intending to conceive by any methods~* Agree to not donate blood from the time of vaccination until 3 months after vaccination~* Have a body mass index (BMI) less than (\<) 40 kilogram per meter square (kg/m\^2)~* Be willing to provide verifiable identification and have means to be contacted and to contact the investigator during the study~Exclusion Criteria:~* Has a contraindication to intramuscular injection (IM) injections and blood draws (example, bleeding disorders)~* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine components (including any of the constituents of the study vaccine)~* History of chronic urticaria (recurrent hives), eczema, or atopic dermatitis~* Has hepatitis B or C infection, including history of treated hepatitis C infection~* Received an active RSV vaccine in a previous RSV vaccine study or an Ad26-vectored vaccine at any time prior to randomization

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort 1 Group 1: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single intramuscular (IM) injection of an Ad26-based RSV vaccine on Day 1.
- Cohort 1 Group 2: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 1) on Day 1.
- Cohort 1 Group 3: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 2) on Day 1.
- Cohort 1 Group 4: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine (low dose 3) on Day 1.
- Cohort 1 Group 5: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive IM injection of placebo on Day 1.
- Cohort 2 Group 6: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
- Cohort 2 Group 7: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 1) on Day 1.
- Cohort 2 Group 8: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive IM injection of placebo on Day 1.
- Cohort 3 Group 9: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine on Day 1.
- Cohort 3 Group 10: RSV Vaccine (Type: EXPERIMENTAL): Participants will receive a single IM injection of an Ad26-based RSV vaccine (high dose 2) on Day 1.
- Cohort 3 Group 11: Placebo (Type: EXPERIMENTAL): Participants will receive IM injection of placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete